Aug 30 |
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
|
Aug 30 |
BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
|
Aug 30 |
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
|
Aug 29 |
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
|
Aug 28 |
BridgeBio Pharma to Participate in September Investor Events
|
Aug 26 |
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
|
Aug 22 |
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
|
Aug 21 |
BridgeBio forms joint venture GondolaBio for rare disease assets
|
Aug 21 |
BridgeBio sends rare disease drugs to new company
|
Aug 19 |
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
|